Management and treatment of chronic urticaria (CU)

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue S3, 2015, Pages 16-32

  Maurer, M ^a   Church, M K ^a   Goncalo M ^b   Sussman, G ^c   Sanchez Borges M ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Centro Medico Docente La Trinidad   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOLOGIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACQUIRED COLD URTICARIA; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CHOLINERGIC URTICARIA; CHRONIC INDUCIBLE URTICARIA; CHRONIC URTICARIA; DELAYED PRESSURE URTICARIA; HUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLAR URTICARIA; URTICARIA; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHRONIC DISEASE; COLD; FEMALE; PREGNANCY; PRESSURE; SUNLIGHT;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHRONIC DISEASE; COLD TEMPERATURE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; OMALIZUMAB; PREGNANCY; PRESSURE; SUNLIGHT; URTICARIA;

EID: 84930454224     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13198     Document Type: Article

References (163)

1. Kaplan AP, Greaves M,. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39: 777-787.
2. Zuberbier T, Aberer W, Asero R, et al,. The EAACI/GALEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update. Allergy 2014; 69: 868-887.
3. Schocket AL,. Chronic urticaria: pathophysiology and etiology, or the what and why. Allergy Asthma Proc 2006; 27: 90-95.
4. Metzger H, Alcaraz G, Hohman R, Kinet JP, Pribluda V, Quarto R,. The receptor with high affinity for immunoglobulin E. Annu Rev Immunol 1986; 4: 419-470.
5. Ishizaka T, Conrad DH,. Binding characteristics of human IgE receptors and initial triggering events in human mast cells for histamine release. Monogr Allergy 1983; 18: 14-24.
6. Stone KD, Prussin C, Metcalfe DD,. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010; 125: S73-S80.
7. Greaves MW,. Pathology and classification of urticaria. Immunol Allergy Clin North Am 2014; 34: 1-9.
8. Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M,. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2014; 135: 337-342.
9. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW,. A serological mediator in chronic idiopathic urticaria-a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114: 583-590.
10. Sabroe RA, Grattan CE, Francis DM, Barr RM, Kobza BA, Greaves MW,. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446-452.
11. Theoharides TC, Alysandratos KD, Angelidou A, et al,. Mast cells and inflammation. Biochim Biophys Acta 2012; 1822: 21-33.
12. Kaplan AP,. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465-474.
13. Staevska M, Popov TA, Kralimarkova T, et al,. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125: 676-682.
14. Maurer M, Rosén K, Hsieh HJ, et al,. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-935.
15. Kaplan A, Ledford D, Ashby M, et al,. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132: 101-109.
16. 1-antihistamines: a randomized placebo-controlled study. J Invest Dermatol 2015; 135: 67-75.
17. Hochhaus G, Brookman L, Fox H, et al,. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19: 491-498.
18. Metz M, Ohanyan T, Church MK, Maurer M,. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014; 73: 57-62.
19. Zuberbier T, Maurer M,. Omalizumab for the treatment of chronic urticaria. Expert Rev Clin Immunol 2015; 11: 171-180.
20. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK,. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569-573.
21. Maurer M, Altrichter S, Bieber T, et al,. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128: 202-209.
22. Saini S, Rosen KE, Hsieh HJ, et al,. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567-573.
23. Krause K, Ardelean E, Kessler B, et al,. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy 2010; 65: 1494-1495.
24. Labrador-Horrillo M, Valero A, Velasco M, et al,. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther 2013; 13: 1225-1228.
25. Metz M, Altrichter S, Ardelean E, et al,. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011; 154: 177-180.
26. Asero R, Casalone R, Iemoli E,. Extraordinary response to omalizumab in a child with severe chronic urticaria. Eur Ann Allergy Clin Immunol 2014; 46: 41-42.
27. Leiva-Salinas M, Frances L, Marin-Cabanas I, Arribas Granados MP, Silvestre JF,. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C. J Eur Acad Dermatol Venereol 2015; 27: 1027-1028.
28. Metz M, Bergmann P, Zuberbier T, Maurer M,. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 247-249.
29. Spector SL, Tan RA,. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007; 99: 190-193.
30. Metz M, Ohanyan T, Church MK, Maurer M,. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014; 150: 288-290.
31. Wedi B, Kapp A,. Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol 2002; 3: 273-282.
32. Weiler JM, Bloomfield JR, Woodworth GG, et al,. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 2000; 132: 354-363.
33. 2LEN position paper. Allergy 2010; 65: 459-466.
34. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M,. Stander S [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series]. Hautarzt 2009; 60: 564-568.
35. FDA, Novartis, and Genentech. Xolair regulatory history and labelling from drugs@FDA. [WWW document]. URL http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (last accessed: 11 August 2014).
36. Novartis Pharmaceuticals UK Ltd. Xolair (omalizumab) 150 mg powder and solvent for solution for injection. UK summary of product characteristics. [WWW document]. Updated December 2013. URL http://www.medicines.org.uk/emc/medicine/17029 (last accessed: 13 January 2014).
37. Casale T, Maurer M, Saini S, et al,. Omalizumab reduced symptoms and improved health-related quality of life (HRQoL) in patients with refractory chronic spontaneous/idiopathic urticaria (CSU/CIU) in three randomised, double-blind, placebo-controlled phase III trials: a post-hoc analysis of percent change from baseline. Allergy 2014; 69 (Suppl 99): 580s (Abstract 1662).
38. Casale T, Maurer M, Saini SS, et al,. Omalizumab improved symptoms in all three phase III trials conducted in patients with inadequately controlled chronic spontaneous/idiopathic urticaria (CSU/CIU): a post-hoc analysis of percent change from baseline. Allergy 2015; 70 (Suppl.6). Latebreaking abstract to be presented at EAACI 2015.
39. Rosen K, Khalil S, Balp M-M, Maurer M,. Omalizumab improves quality of life (QoL) in patients with symptomatic chronic spontaneous/idiopathic urticaria (CSU/CIU) as assessed by the Dermatology Life Quality Index (DLQI). Presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI), Houston, TX, USA, 20-24 February 2015 (Poster P409).
40. 2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
41. 2LEN/EDF guideline: management of urticaria. Allergy 2006; 61: 321-331.
42. Husz S, Toth-Kasa I, Kiss M, Dobozy A,. Treatment of cold urticaria. Int J Dermatol 1994; 33: 210-213.
43. Soter NA,. Urticaria: current therapy. J Allergy Clin Immunol 1990; 86: 1009-1014.
44. Schoepke N, Abajian M, Church MK, Magerl M,. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol 2014; Dec 18. doi: 10.1111/ced.12547. [Epub ahead of print].
45. Abajian M, Schoepke N, Altrichter S, Zuberbier T, Maurer M,. Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am 2014; 34: 73-88.
46. European Academy of Allergy and Clinical Immunology (EAACI). Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology [draft guidance]. [WWW document]. 12 June 2013. URL http://www.eaaci.org/attachments/Anaphylaxis%20guidelines%20Draft%204.5%202013%2006%20.pdf (last accessed: 13 February 2014).
47. Schoepke N, Mlynek A, Weller K, Church MK, Maurer M,. Symptomatic dermographism: an inadequately described disease. J Eur Acad Dermatol Venereol 2015; 29: 708-712.
48. Bettley FR,. A device for the measurement of factitious urticaria. J Invest Dermatol 1962; 39: 1.
49. Kontou-Fili K, Borici-Mazi R, Kapp A, Matjevic LJ, Mitchel FB,. Physical urticaria: classification and diagnostic guidelines. An EAACI position paper. Allergy 1997; 52: 504-513.
50. Abajian M, Mlynek A, Maurer M,. Physical urticaria. Curr Allergy Asthma Rep 2012; 12: 281-287.
51. Toda S, Takahagi S, Mihara S, Hide M,. Six cases of antihistamine-resistant dermographic urticaria treated with oral ciclosporin. Allergol Int 2011; 60: 547-550.
52. Wallengren J, Isaksson A,. Urticarial dermographism: clinical features and response to psychosocial stress. Acta Derm Venereol 2007; 87: 493-498.
53. Dice JP,. Physical urticaria. Immunol Allergy Clin North Am 2004; 24: 225-246.
54. Lawlor F, Black AK, Murdoch RD, Greaves MW,. Symptomatic dermographism: wealing, mast cells and histamine are decreased in the skin following long-term application of a potent topical corticosteroid. Br J Dermatol 1989; 121: 629-634.
55. Jáuregui I, Ferrer M, Montoro J, et al,. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol 2007; 17: 41-52.
56. Clinicaltrials.gov. Urticaria facticia treatment with omalizumab (UFO). (NCT02169115). [WWW document]. URL https://www.clinicaltrials.gov/ct2/show/NCT02169115 (last accessed: 2 March 2015).
57. Alangari AA, Twarog FJ, Shih MC, Schneider LC,. Clinical features and anaphylaxis in children with cold urticaria. Pediatrics 2004; 113: e313-e317.
58. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M,. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123: 672-679.
59. Kring-Tannert L, Stahl SP, Bjerremann JL, Maurer M, Bindslev-Jensen C,. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology 2012; 224: 101-105.
60. Weinstein ME, Wolff AH, Bielory L,. Efficacy and tolerability of second- and third-generation antihistamines in the treatment of acquired cold urticaria: a meta-analysis. Ann Allergy Asthma Immunol 2010; 104: 518-522.
61. Magerl M, Pisarevskaja D, Staubach P, Martus P, Church MK, Maurer M,. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. Br J Dermatol 2012; 166: 1095-1099.
62. Metz M, Scholz E, Ferran M, Izquierdo I, Giménez-Arnau A, Maurer M,. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010; 104: 86-92.
63. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M,. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921-928.
64. Delorme N, Drouet M, Thibaudeau A, Verret JL,. Cold-induced urticaria. Allerg Immunol (Paris) 2002; 34: 255-258.
65. Marsland AM, Beck MH,. Cold urticaria responding to systemic ciclosporin. Br J Dermatol 2003; 149: 214-215.
66. Kozaru T, Fukunaga A, Taguchi K, et al,. Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int 2011; 60: 277-281.
67. Poon E, Seed PT, Greaves MW, Kobza-Black A,. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999; 140: 667-671.
68. Feinberg JH, Toner CB,. Successful treatment of disabling cholinergic urticaria. Mil Med 2008; 173: 217-220.
69. Nakamizo S, Egawa G, Miyachi Y, Kabashima K,. Cholinergic urticaria: pathogenesis-based categorization and its treatment options. J Eur Acad Dermatol Venereol 2012; 26: 114-146.
70. Altrichter S, Wosny K, Maurer M,. Successful treatment of cholinergic urticaria with methantheliniumbromide. J Dermatol 2015; 42: 422-424.
71. Sheraz A, Halpern S,. Cholinergic urticaria responding to botulinum toxin injection for axillary hyperhidrosis. Br J Dermatol 2013; 168: 1369-1370.
72. Wong E, Eftekhari N, Greaves MW, Ward AM,. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol 1987; 116: 553-556.
73. La Shell MS, England RW,. Severe refractory cholinergic urticaria treated with danazol. J Drugs Dermatol 2006; 5: 664-667.
74. Du-Thanh A, Debu A, Lalheve P, Guillot B, Dereure O, Peyron JL,. Solar urticaria: a time-extended retrospective series of 61 patients and review of literature. Eur J Dermatol 2013; 23: 202-207.
75. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE,. Systemic photoprotection in solar urticaria with a-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH. Br J Dermatol 2011; 164: 407-414.
76. Pont M, Delaporte E, Bonnevalle A, Thomas P,. [Solar urticaria: pre-PUVA UVA desensitization]. Ann Dermatol Venereol 2000; 127: 296-299.
77. Beissert S, Stander H, Schwarz T,. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol 2000; 42: 1030-1032.
78. Masuoka E, Fukunaga A, Kishigami K, et al,. Successful and long-lasting treatment of solar urticaria with ultraviolet A rush hardening therapy. Br J Dermatol 2012; 167: 198-201.
79. Eguino P, Lasa O, Gardeazábal J, Díaz-Pérez JL,. [Solar urticaria. Study of 20 cases]. Actas Dermosifiliogr 2005; 96: 25-29.
80. Botto NC, Warshaw EM,. Solar urticaria. J Am Acad Dermatol 2008; 59: 909-920.
81. Faurschou A, Wulf HC,. Synergistic effect of broad-spectrum sunscreens and antihistamines in the control of idiopathic solar urticaria. Arch Dermatol 2008; 144: 765-769.
82. Duchini G, Bäumler W, Bircher AJ, Scherer K,. Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 2011; 27: 336-337.
83. Webb LM, Mikita CP,. Solar urticaria. Allergy Asthma Proc 2009; 30: 563-565.
84. Epstein JH, Vandenberg JJ, Wright WL,. Solar urticaria. Arch Dermatol 1963; 88: 135-141.
85. Edstrom DW, Ros AM,. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed 1997; 13: 61-63.
86. Güzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M,. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63: 1563-1565.
87. Cassano N, Mastrandrea V, Vestita M, Vena GA,. An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatment. Dermatol Ther 2009; 2 (Suppl. 1): S22-S26.
88. Grundmann SA, Kiefer S, Luger TA, Brehler R,. Delayed pressure urticaria-dapsone heading for first-line therapy? J Dtsch Dermatol Ges 2011; 9: 908-912.
89. Lawlor F, Black AK,. Delayed pressure urticaria. Immunol Allergy Clin North Am 2004; 24: 247-258.
90. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A,. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34: 1401-1407.
91. Powell RJ, Du Toit GL, Siddique N, et al,. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37: 631-650.
92. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S,. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294-301.
93. Samarasinghe V, Marsland AM,. Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed-pressure urticaria. Clin Exp Dermatol 2012; 37: 741-743.
94. Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M,. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol 2007; 119: 752-754.
95. Dawn G, Urcelay M, Ah-Weng A, O'Neill SM, Douglas WS,. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol 2003; 149: 836-840.
96. Perez A, Woods A, Grattan CE,. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162: 191-194.
97. Church MK, Weller K, Stock P, Maurer M,. Chronic spontaneous urticaria in children: itching for insight. Pediatr Allergy Immunol 2011; 22: 1-8.
98. Bailey E, Shaker M,. An update on childhood urticaria and angioedema. Curr Opin Pediatr 2008; 20: 425-430.
99. Novembre E, Cianferoni A, Mori F, et al,. Urticaria and urticaria related skin condition/disease in children. Eur Ann Allergy Clin Immunol 2008; 40: 5-13.
100. Liu TH, Lin YR, Yang KC, Chou CC, Chang YJ, Wu HP,. First attack of acute urticaria in pediatric emergency department. Pediatr Neonatol 2008; 49: 58-64.
101. Wedi B, Raap U, Wieczorek D, Kapp A,. Urticaria and infections. Allergy Asthma Clin Immunol 2009; 5: 10.
102. Sackesen C, Sekerel BE, Orhan F, Kocabas CN, Tuncer A, Adalioglu G,. The etiology of different forms of urticaria in childhood. Pediatr Dermatol 2004; 21: 102-108.
103. Chansakulporn S, Pongpreuksa S, Sangacharoenkit P, et al,. The natural history of chronic urticaria in childhood: a prospective study. J Am Acad Dermatol 2014; 71: 663-668.
104. Sahiner UM, Civelek E, Tuncer A, et al,. Chronic urticaria: etiology and natural course in children. Int Arch Allergy Immunol 2011; 156: 224-230.
105. del Cuvillo A, Sastre J, Montoro J, et al,. Use of antihistamines in pediatrics. J Investig Allergol Clin Immunol 2007; 17 (Suppl 2): 28-40.
106. Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA,. Antihistamine use in children. Arch Dis Child Educ Pract Ed 2014; doi: 10.1136/archdischild-2013-304446. [Epub ahead of print].
107. Mushtaq T, Ahmed SF,. The impact of corticosteroids on growth and bone health. Arch Dis Child 2002; 87: 93-96.
108. de Silva NL, Damayanthi H, Rajapakse AC, Rodrigo C, Rajapakse S,. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol 2014; 10: 24.
109. Merck & Co. SINGULAIR® (montelukast): prescribing information. [WWW document]. Updated June 2013. Available at: http://www.merck.com/product/usa/pi-circulars/s/singulair/singulair-pi.pdf (last accessed: 13 January 2014).
110. Doshi DR, Weinberger MM,. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol 2009; 26: 409-413.
111. Neverman L, Weinberger M,. Treatment of chronic urticaria in children with antihistamines and cyclosporine. J Allergy Clin Immunol Pract 2014; 2: 434-438.
112. Sussman G, Hebert J, Barron C, et al,. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014; 112: 170-174.
113. Uysal P, Eller E, Mortz CG, Bindslev-Jensen C,. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. J Allergy Clin Immunol 2014; 133: 914-915.
114. Simons FE, Simons KJ,. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999; 36: 329-352.
115. Yap YG, Camm AJ,. Potential cardiac toxicity of H1-antihistamines. Clin Allergy Immunol 2002; 17: 389-419.
116. Hilbert J, Moritzen V, Parks A, et al,. The pharmacokinetics of loratadine in normal geriatric volunteers. J Int Med Res 1988; 16: 50-60.
117. Ghosal A, Gupta S, Ramanathan R, et al,. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett 2009; 3: 162-170.
118. Asero R, Tedeschi A, Cugno M,. Treatment of refractory chronic urticaria: current and future therapeutic options. Am J Clin Dermatol 2013; 14: 481-488.
119. Kadar L, Kivity S,. Urticaria and angioedema in pregnancy. Curr Dermatol Rep 2013; 2: 236-242.
120. Sachdeva S,. The dermatoses of pregnancy. Indian J Dermatol 2008; 53: 103-105.
121. Food and Drug Administration (FDA). FDA. 21 CFR part 201. 2008. [WWW document]. URL http://www.gpo.gov/fdsys/pkg/FR-2008-05-29/pdf/E8-11806.pdf (last accessed: 20 January 2015).
122. Lucas BD Jr, Purdy CY, Scarim SK, Benjamin S, Abel SR, Hilleman DE,. Terfenadine pharmacokinetics in breast milk in lactating women. Clin Pharmacol Ther 1995; 57: 398-402.
123. Hilbert J, Radwanski E, Affrime MB, Perentesis G, Symchowicz S, Zampaglione N,. Excretion of loratadine in human breast milk. J Clin Pharmacol 1988; 28: 234-239.
124. Diav-Citrin O, Shechtman S, Aharonovich A, et al,. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111: 1239-1243.
125. Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA,. Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf 2014; 13: 1667-1698.
126. Kallen B,. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11: 146-152.
127. Pedersen L, Skriver MV, Norgaard M, Sorensen HT,. Maternal use of Loratadine during pregnancy and risk of hypospadias in offspring. Int J Med Sci 2006; 3: 21-25.
128. Weber-Schoendorfer C, Schaefer C,. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008; 26: 19-23.
129. Clift DE, Thorn RJ, Passarelli EA, et al,. Effects of embryonic cyclosporine exposures on brain development and behavior. Behav Brain Res 2015; 282: 117-124.
130. McGee DC,. Steroid use during pregnancy. J Perinat Neonatal Nurs 2002; 16: 26-39.
131. Koren G, Sarkar M, Einarson A,. Safety of using montelukast during pregnancy. Can Fam Physician 2010; 56: 881-882.
132. Vieira Dos Santos R, Locks BB, de Rabello SJ, Maurer M,. Effects of omalizumab in a patient with three types of chronic urticaria. Br J Dermatol 2014; 170: 469-471.
133. Namazy J, Cabana MD, Scheuerle AE, et al,. The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015; 135: 407-412.
134. Kuprys-Lipinska I, Tworek D, Kuna P,. Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies. Postepy Dermatol Alergol 2014; 31: 104-107.
135. Kowalski ML, Asero R, Bavbek S, et al,. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013; 68: 1219-1232.
136. Doeglas HM,. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br J Dermatol 1975; 93: 135-144.
137. Moore-Robinson M, Warin RP,. Effect of salicylates in urticaria. Br Med J 1967; 4: 262-264.
138. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A,. Subtypes of chronic urticaria in patients attending allergy clinics in Venezuela. Eur Ann Allergy Clin Immunol 2014; 46: 210-215.
139. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, Gonzalez-Aveledo L,. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2015; 29: 698-701.
140. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A,. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004; 113: 771-775.
141. Asero R,. Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: what differentiates patients with and without underlying chronic spontaneous urticaria? Int Arch Allergy Immunol 2014; 163: 114-118.
142. Kostis JB, Kim HJ, Rusnak J, et al,. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165: 1637-1642.
143. Byrd JB, Adam A, Brown NJ,. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006; 26: 725-737.
144. Brown NJ, Ray WA, Snowden M, Griffin MR,. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60: 8-13.
145. Gosmanov AR, Fontenot EC,. Sitagliptin-associated angioedema. Diabetes Care 2012; 35: e60.
146. Sánchez-Borges M, Gonzalez-Aveledo LA,. Angiotensin-converting enzyme inhibitors and angioedema. Allergy Asthma Immunol Res 2010; 2: 195-198.
147. Rasmussen ER, Mey K, Bygum A,. Angiotensin-converting enzyme inhibitor-induced angioedema-a dangerous new epidemic. Acta Derm Venereol 2014; 94: 260-264.
148. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr,. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008; 100: 327-332.
149. Caballero T, Baeza ML, Cabanas R, et al,. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 2011; 21: 333-347.
150. Sabroe RA, Black AK,. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136: 153-158.
151. Gelee B, Michel P, Haas R,. Boishardy F. [Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate]. Rev Med Interne 2008; 29: 516-519.
152. Nielsen EW, Gramstad S,. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 2006; 50: 120-122.
153. Rasmussen ER, Bygum A,. ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate. BMJ Case Rep 2013 Oct 4; 2013. doi: 10.1136/bcr-2013-200652.
154. Bas M, Greve J, Stelter K, et al,. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010; 56: 278-282.
155. Clinicaltrials.gov. Blinded safety and efficacy placebo controlled study of icatibant for angiotensin converting enzyme inhibitor induced angioedema. (NCT01919801). [WWW document]. URL https://clinicaltrials.gov/ct2/show/NCT01919801 (last accessed: 2 March 2015).
156. Bas M, Greve J, Stelter K, et al,. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 2015; 372: 418-425.
157. Bernstein JA, Moellman JJ, Collins SP, Hart KW, Lindsell CJ,. Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. Ann Allergy Asthma Immunol 2015; 114: 245-249.
158. Malde B, Regalado J, Greenberger PA,. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007; 98: 57-63.
159. Boyce JA,. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117: 1415-1418.
160. Brodská P, Schmid-Grendelmeier P,. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol 2012; 4: 275-280.
161. Sabroe RA,. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol 2010; 35: e127-e129.
162. Waibel KH, Reese DA, Hamilton RG, Devillez RL,. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010; 125: 490-491.
163. Bindslev-Jensen C, Skov PS,. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010; 65: 138-139.